Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 17, 2014

Primary Completion Date

September 8, 2017

Study Completion Date

September 8, 2017

Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
DRUG

Iron infusion

5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.

DRUG

Normal saline infusion

Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01978535 - Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) | Biotech Hunter | Biotech Hunter